Cory Kasimov Recent News
Is Keryx Still A Good Buy After Weak Prescription Data?
Analysts Respond To Pharmacyclics' Q4 Results
J.P. Morgan Is Watching This 'Curve Ball' At Gilead
Gilead Sciences Spikes Higher As Barron's Suggests Looking Beyond Hepatitis-C
Novavax, Inc. Jumps 7% Amid JP Morgan Initiation
J.P. Morgan Sees Sangamo Biosciences, Inc. As Attractive Investment Opportunity
UPDATE: J.P. Morgan Initiates Coverage On Sangamo Biosciences On Potentially Disruptive Future
UPDATE: Vivus Down Nearly 12% After JP Morgan Downgrade on Lackluster Qsymia News
UPDATE: J.P. Morgan Reiterates on Keryx Biopharmaceuticals on Model Update After Positive NDD-CKD Data
UPDATE: J.P. Morgan Initiates Coverage on Isis Pharmaceuticals, Awaiting Better Entry Point
UPDATE: J.P. Morgan Initiates Coverage on Pharmacyclics on Ibrutinib Potential
UPDATE: J.P. Morgan Initiates bluebird bio at Overweight on Unique & Necessary Medical Products
UPDATE: J.P. Morgan Initiates Keryx Biopharmaceuticals at Overweight on Increasing Comfort With Key Controversies
UPDATE: J.P. Morgan Downgrades Rigel Pharmaceuticals to Neutral Following AZN Decision
UPDATE: J.P. Morgan Raises PT on Aegerion Pharmaceuticals in Continuing Doc Rounds Series
JP Morgan Upgrades Orexigen Therapeutics to Overweight
Ariad Pharmaceuticals' New Drug Shows Promise, Says JP Morgan
J.P. Morgan Maintains Human Genome Sciences (HGSI) Overweight Rating